http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104769432-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae10212794160b34478f0d05b6ab6fd7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2013-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7f2b0198d1bf063e333220537ff701b |
| publicationDate | 2015-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104769432-A |
| titleOfInvention | Resistance biomarkers to HDAC inhibitors |
| abstract | Provided herein are methods for identifying a cancer patient at risk of being resistant to treatment with an HDAC inhibitor comprising obtaining a tumor sample from said cancer patient; detecting testis-specific Y-encoded-like protein 5 (TSPYL5) expression in the sample the presence of ; quantify the level of TSPYL5 expression in the sample, wherein a high level of TSPYL5 expression correlates with resistance to HDAC inhibitor treatment relative to a defined TSPYL5 expression threshold; and applying said correlation to identify Cancer patients at risk of resistance to HDAC inhibitor therapy. Also provided herein is a method for identifying a cancer patient with an increased likelihood of positive clinical response to treatment with an HDAC inhibitor comprising obtaining a tumor sample from said cancer patient; detecting a testis-specific Y-encoded-like protein in the sample the presence of 5 (TSPYL5) expression; quantifying the level of TSPYL5 expression in the sample, wherein a low level of TSPYL5 expression, relative to a defined TSPYL5 expression threshold, identifies the likelihood of a positive clinical response to HDAC inhibitor treatment increased cancer patients. Related methods and compositions are also provided herein. |
| priorityDate | 2012-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.